Publications et Communications

Publications

2017

The mTORC1/2 inhibitor AZD8055 strengthens the efficiency of the MEK inhibitor trametinib to reduce the Mcl-1/[Bim and Puma] ratio and to sensitize ovarian carcinoma cells to ABT-737. 

Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.

Molecular Cancer Therapeutics. 2017, 16(1):102-115.

2016

An overview of long non-coding RNAs in ovarian cancer.
Meryet-Figuière M, Lambert B, Gauduchon P, Brotin E, Poulain L, Denoyelle C.

Oncotarget. 2016 Jul 12;7(28):44719-44734.

2016

Towards a new standardized method for circulating miRNAs profiling in clinical studies: interest of the exogenous normalization to enhance miRNA signature accuracy.
Vigneron N, Meryet-Figuière M, Guttin A, Issartel JP, Lambert B, Briand M, Leconte A, Lheureux S, Clarisse B, Krieger S, Joly F, Gauduchon P, Poulain L, Denoyelle C.

Molecular Oncology. 2016,  Aug;10(7):981-92.

2015

Quantifying and correcting for tail vein extravasation in small animal PET scans in cancer research: is there an impact on therapy assessment?
Lasnon C, Dugue AE, Briand M, Dutoit S, Aide N.

European Journal of Nuclear Medicine and Molecular Imaging Research 2015 Dec;5(1):61.

2015

Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.
Bonnefond ML, Lambert B, Giffard F, Abeilard E, Brotin E, Louis MH, Gueye MS, Gauduchon P, Poulain L, N'Diaye M.

Apoptosis. 2015 Apr;20(4):535-50.

2015

First Evidence that Oligopyridines, Alpha Helix Foldamers, Inhibit Mcl-1 and Sensitize Ovarian Carcinoma Cells to Bcl-xL-Targeting Strategies.
Gloaguen C, Voisin-Chiret AS, Sopkova-de Oliveira Santos J, Fogha J, Gautier F, De Giorgi M, Burzicki G, Perato S, Pétigny-Lechartier C, Simonin-Le Jeune K, Brotin E, Goux D, N'Diaye M, Lambert B, Louis MH, Ligat L, Lopez F, Juin P, Bureau R, Rault S, Poulain L.

Journal of Medicinal Chemistry 2015 Feb 26;58(4):1644-68.

2015

miRNAs as tools for tailoring personalized therapeutic strategies in ovarian carcinoma.
Lambert B, Meryet-Figuière M, Gauduchon P, Vigneron N, Brotin E, Poulain L and Denoyelle C.

RNA and Disease, 2015 in press.

 

2015

NEMA NU 4-Optimized Reconstructions for Therapy Assessment in Cancer Research with the Inveon Small Animal PET/CT System.
Lasnon C, Dugue AE, Briand M, Blanc-Fournier C, Dutoit S, Louis MH, Aide N.

Mol Imaging Biol. 2015 Jun;17(3):403-12.

2015

Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S, N’Diaye M, Blanc-Fournier C, Dugue AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, Grellard JM, Crouet H, Martin S, Joly F, Poulain L.

Int J Cancer. 2015 Mar 1;136(5):E340-50.

2015

BMP-2, Hypoxia, and COL1A1/HtrA1 siRNAs Favor Neo-Cartilage Hyaline Matrix Formation in Chondrocytes.
Ollitrault D, Legendre F, Drougard C, Briand M, Benateau H, Goux D, Chajra H, Poulain L, Hartmann D, Vivien D, Shridhar V, Baldi A, Mallein-Gerin F, Boumediene K, Demoor M, Galera P.

Tissue Eng Part C Methods. 2015 Feb;21(2):133-47.

2015

Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death.
Kafara P, Icard P, Guillamin M, Schwartz L, Lincet H.

J Ovarian Res. 2015 Jun 12;8(1):36.

 

2015

How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?
Lincet H, Icard P.

Oncogene. 2015 Jul;34(29):3751-9.

2014

miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation.
Denoyelle C, Lambert B, Meryet-Figuière M, Vigneron N, Brotin E, Lecerf C, Abeilard E, Giffard F, Louis MH, Gauduchon P, Juin P, Poulain L.

Cell Death Dis. 2014 Oct 9;5:e1445.

2014

PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A, Villedieu M, Petigny C, Brotin E, Louis MH, Abeillard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.

Cancer Letters 2014 Jun 28;348(1-2):38-49.

2014

The metabolic cooperation between cells in solid cancer tumors.
Icard P, Kafara P, Steyaert JM, Schwartz L, Lincet H.

BBA Review on Cancer 2014 Aug;1846(1):216-25.

2014

Metabolic treatment of cancer: intermediate results of a prospective case.
Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM.

Anticancer Res 2014 Feb;34(2):973-80.

 

2014

Staging the axilla in breast cancer patients with (18)F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?
Bellevre D, Blanc Fournier C, Switsers O, Dugué AE, Levy C, Allouache D, Desmonts C, Crouet H, Guilloit JM, Grellard JM, Aide N.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1103-12.

 

2014

The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria.
Quak E, Hovhannisyan N, Lasnon C, Fruchart C, Vilque JP, Musafiri D, Aide N.

Haematologica. 2014 Jun;99(6):e84-5.

 

2014

Diuretic 18 F-FDG PET/CT for therapy monitoring in urothelial bladder cancer.
Coquan E, Lasnon C, Joly F, Lefort JM, Aide N.

Eur J Nucl Med Mol Imaging 2014.

 

2013

(18)F-FDG is a surrogate marker of therapy response and tumor recovery after drug withdrawal during treatment with a dual PI3K/mTOR inhibitor in a preclinical model of cisplatin-resistant ovarian cancer.
Lheureux S, Lecerf C, Briand M, Louis MH, Dutoit S, Jebahi A, Giffard F, Fournier CB, Batalla A, Poulain L, Aide N.

Transl Oncol 2013 Oct 1;6(5):586-95.

2013

Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells.
Lincet H, Kafara P, Giffard F, Abeilard-Lemoisson E, Duval M, Louis MH, Poulain L, Icard P.

J Ovarian Res 2013 Oct 8;6(1):72.

2013

Rapid and soft formulation of folate-functionalized nanoparticles for the targeted delivery of tripentone in ovarian carcinoma.
Tomasina J, Poulain L, Abeilard E, Giffard F, Brotin E, Carduner L, Carreiras F, Gauduchon P,  Rault S, Malzert-Freon A.

International Journal of Pharmaceutics 2013 Dec 15;458(1):197-207.

2013

Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions.
Beauregard JM, Giraudet AL, Aide N, Hofman MS, Blum R, Drummond E, Roselt P, Hicks RJ.

Nucl Med Commun 2013 Jun;34(6):521-6.

2013

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
Bertucci F, Finetti P, Roche H, Le Doussal JM, Marisa L, Martin AL, Lacroix-Triki M, Blanc-Fournier C, Jacquemier J, Peyro-Saint-Paul H, Viens P, Sotiriou C, et al.

Ann Oncol 2013 Mar;24(3):625-32.

2013

Biodistribution and imaging of [99mTc]-HYNIC-RGD in MDA-MB-231 and NTERA-2 cancer cell xenografts.
Bohn P, Modzelewski R, Rouvet J, Briand M, Dutoit S, Pille JY, Picquenot JM, Aide N, Vera P.

Nucl Med Commun 2013 Jul;34(7):709-17.

2013

The cancer tumor: a metabolic parasite?
Icard P, Lincet H.

Bull Cancer 2013 May 1;100(5):427-33.

2013

Morbidity, mortality and survival after 110 consecutive bilobectomies over 12 years.
Icard P, Heyndrickx M, Guetti L, Galateau-Salle F, Rosat P, Le Rochais JP, Hanouz JL.

Interact Cardiovasc Thorac Surg 2013 Feb;16(2):179-85.

2013

Does bilobectomy offer satisfactory long-term survival outcome for non-small cell lung cancer?
Icard P, Heyndrickx M, Galateau-Salle F, Rosat P, Lerochais JP, Gervais R, Zalcman G, Hanouz JL.

Ann Thorac Surg 2013 May;95(5):1726-33.

2013

Contrast-enhanced small-animal PET/CT in cancer research: strong improvement of diagnostic accuracy without significant alteration of quantitative accuracy and NEMA NU 4-2008 image quality parameters.
Lasnon C, Quak E, Briand M, Gu Z, Louis MH, Aide N.

EJNMMI Res 2013;3(1):5.

2013

Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.
Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, Aide N.

Eur J Nucl Med Mol Imaging 2013 Jul;40(7):985-96.

2013

Quality of life in long-term cervical cancer survivors: a population-based study.
Le BG, Mercier M, Woronoff AS, Guizard AV, Abeilard E, Caravati-Jouvenceaux A, Klein D, Velten M, Joly F.

Gynecol Oncol 2013 Apr;129(1):222-8.

2013

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.

Apoptosis 2013 Apr;18(4):492-508.

2013

Nanocarriers for the targeted treatment of ovarian cancers.
Tomasina J, Lheureux S, Gauduchon P, Rault S, Malzert-Freon.

Biomaterials 2013 Jan;34(4):1073-101.

2013

Sensitization of ovarian carcinoma cells to Bcl-xL-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family.
Tomasina J, Malzert-Freon A, Giffard F, Brotin E, Louis MH, Abeilard E, Rault S, Gauduchon P, Poulain L.

J Ovarian Res 2013 Jun 5;6(1):38.

2013

A rare case of a tumour with two components in a young patient with diagnosed Crohn's disease].
Lheureux S, Blanc-Fournier C, Chasles J, El HA, Michels JJ.

Ann Pathol 2013 Apr;33(2):122-4

2013

F18-Choline, a novel PET tracer for parathyroid adenoma ?
Quak E, Lheureux S, Reznik Y, Bardet S, Aide N.

J Clin Endocrinol Metab 2013 Jun 20.

2012

siPGK1 Sensitizes Chemoresistant Human Ovarian Cancer Cell Lines to Cisplatin.
Lepleux C, Abeilard-Lemoisson E, Duval M, Icard P, Lincet H.

Anticancer Res 2012 Oct;32(10):4277-86.

2012

A global view of the biochemical pathways that might be involved in cancer cells.
Icard P. & Lincet H.

Biochim Biophys Acta 2012 Dec;1826(12):423-33.

2012

Experimental results using 3-bromopyruvate in mesothelioma: in vitro and in vivo studies.
Icard P, Zhang X-D, Lemoisson E, Louis M-H, Allouche S, Lincet H, Poulain L.

Jour Bioenergetics of membranes 2012;44(1):81-90.

2012

The central role of citrate in the metabolism of cancer cells.
Icard P and Lincet H.

Biomedical Research. Special Issue (Cancer Metabolism), Vol 23, February 2012ière

2012

Understanding the central role of citrate in the metabolism of cancer cells.
Icard P, Poulain L, Lincet H.

Biochim Biophys Acta 2012 Jan;1825(1):111-6. Review.

2012

Comparative 2D-DIGE proteomic analysis of ovarian carcinoma cells: toward a reorientation of biosynthesis pathways associated with acquired platinum resistance.
Lincet H, Guével B, Pineau C, Allouche S, Lemoisson E, Poulain L, Gauduchon P.

J Proteomics 2012 Feb 2;75(4):1157-69.

2012

PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved.
Ray-Coquard I, Chauvin F, Leblanc E, Caux C, Hoarau H, Bonnetain F, Christophe V, Sastre-Garau X, Lazennec G, Poulain L, Haie-Meder C, Pujade-Lauraine E, Salzet M, Deutsch E, Devouassoux M, Penault Llorca F, Lecuru F, Taieb S, Arveux P, Theillet C, Joly F.

Bull Cancer 2012 Apr 1;99(4):479-498.

2011

α(v)β (3) imaging can accurately distinguish between mature teratoma and necrosis in (18)F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study.
Aide N, Briand M, Bohn P, Dutoit S, Lasnon C, Chasle J, Rouvet J, Modzelewski R, Vela A, Deslandes E, Vera P, Poulain L, Carreiras F.

Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):323-33.

2011

A dual radiologic contrast agent protocol for 18F-FDG and 18F-FLT PET/CT imaging of mice bearing abdominal tumors.
Aide N, Kinross K, Beauregard JM, Neels O, Potdevin T, Roselt P, Dorow D, Cullinane C, Hicks R.

Molecular imaging and biology 2011 Jun;13(3):518-25.

2011

Towards a computer aided diagnosis system dedicated to virtual microscopy based on stereology sampling and diffusion maps.
Belhomme P, Oger M, Michels JJ, Plancoulaine B, Herlin P.

Diagn Pathol 2011 Mar 30;6 Suppl 1:S3.

2011

Two novel variants in the 3'UTR of the BRCA1 gene in familial breast and/or ovarian cancer.
Lheureux S, Lambert B, Krieger S, Legros A, Vaur D, Denoyelle C, Berthet P, Poulain L, Hardouin A.

Breast Cancer Res Treat. 2011 Feb;125(3):885-91.

2011

Citrate induces apoptotic cell death: a promising way to treat gastric carcinoma?
Lu Y, Zhang X, Zhang H, Lan J, Huang G, Varin E, Lincet H, Poulain L, Icard P.

Anticancer Res. 2011 Mar;31(3):797-805.

 

 

2010

18F-Fluorothymidine PET as a surrogate marker of drug efficacy during mTOR inhibition by Everolimus in SKOV3 cisplatin-resistant ovarian tumours: a preclinical study.
Aide N, Kinross K, Cullinane C, Roselt P, Waldeck K, Neels O, Dorow D, MacArthur G, Hicks R.

Journal of Nuclear Medicine 2010 Oct;51(10):1559-64.

2010

High throughput small animal PET imaging in cancer research : evaluation of the capability of the Inveon scanner to image four mice simultaneously.
Aide N, Desmonts C, Briand M, Meyert-Figuiere M, Poulain L.

Nuclear Medicine Communications. 2010 Oct;31(10):851-8.

2010

High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications.
Aide N, Desmonts C, Beauregard JM, Beyer T, Kinross K, Roselt P, Neels O, Agostini D, Bardet S, Bouvard G, Hicks RJ.

Eur J Nucl Med Mol Imaging. 2010 May;37(5):991-1001.

2010

Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
Brotin E, Meryet-Figuière M, Simonin K, Duval RE, Villedieu M, Leroy-Dudal J, Saison-Behmoaras E, Gauduchon P, Denoyelle C, Poulain L.

Int J Cancer 2010. Feb 15;126(4):885-95.

2010

Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin.
Kellouche S, Fernandes J, Leroy-Dudal J, Gallet O, Dutoit S, Poulain L, Carreiras F.

Tumour Biol. 2010 Apr;31(2):129-39.

2010

Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma.
Labiche A, Heutte N, Herlin P, Gauduchon P, Elie N.

International Journal of Gynecological Cancer. 2010 Jan;20(1):28-33.

2010

Influence of the introduction of a solubility enhancer on the formulation of lipidic nanoparticles with improved drug loading rates.
Malzert-Fréon A, Saint-Lorant G, Hennequin D, Gauduchon P, Poulain L, Rault S.

Eur J Pharm Biopharm. 2010 Jun;75(2):117-27.

2010

Wavelet-based multiscale texture segmentation : Application to stromal compartment characterization on virtual slides. Signal Processing; Special Section on Processing and Analysis of High-Dimensional Masses of Image and Signal Data.
Signolle N, Revenu M, Plancoulaine B, Herlin P.

2010 Aug;90:8, 2412-2422.

2010

Down-regulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
Varin E, Denoyelle C, Brotin E, Meryet-Figuière M, Giffard F, Abeilard E, Goux D, Gauduchon P, Icard P, Poulain L.

Carcinogenesis. 2010 Jun;31(6):984-93

2009

Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts : early flare response does not reflect refractory disease.
Aide N, Poulain L, Briand M, Dutoit S, Allouche S, Labiche A, Ngo-Van Do A, Nataf V, Batalla A, Gauduchon P, Talbot JN, Montravers F.

Eur J Nucl Med Mol Imaging. 2009;36(3):396-405.

2009

Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma. Histology Histopathology.
Labiche A, Elie N, Herlin P, Denoux Y, Crouet H, Heutte N, Joly F, Héron JF, Gauduchon P, Henry-Amar M.

2009 Apr;24(4):425-35.

2009

Classification of low resolution virtual slides from breast tumor sections: comparison between global and local analysis.
Oger M, Belhomme P, Gurcan M.

Conf Proc IEEE Eng Med Biol Soc. 2009;6671-4.

2009

Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.
Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, N'diaye M, Denoyelle C, Gauduchon P, Poulain L.

Mol Cancer Ther. 2009 Nov;8(11):3162-70.

2009

Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice.
Zhang X, Varin E, Briand M, Allouche S, Heutte N, Schwartz L, Poulain L, Icard P.

Anticancer Res. 2009 Apr;29(4):1443-8.

2009

Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin.
Zhang X, Varin E, Allouche S, Lu Y, Poulain L, Icard P.

Anticancer Res. 2009 Apr;29(4):1249-54.

2008

Usefulness of automatic quantification of immunochemical staining on whole tumor sections for correlation with oncological small animal PET studies: an example with cell proliferation, glucose transporter 1 and FDG.
Aide N, Labiche A, Herlin P, Paciencia M, Poulain L, Dutoit S, Montravers F, Gauduchon P, Chasle J.

Mol Imaging Biol. 2008 Sep;10(5):237-44.

2008

A potential contribution of virtual slides and automatic image processing to the estimation of the vascularization of cranial sutures.
Dorandeu A, Plancoulaine B, Leonetti G, Herlin P.

Annales de Pathologie. 2008;28(4):342-346.

2008

Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro.
Heyman L, Kellouche S, Fernandes J, Dutoit S, Poulain L, Carreiras F.

Tumour Biol. 2008;29(4):231-44.

2008

Automated region of interest retrieval and classification using spectral analysis.
Oger M, Belhomme P, Klossa J, Michels JJ, Elmoataz A.

In Diagnostic Pathology Journal. 2008;3 Suppl 1:S17.

2007

Improvement of semi-quantitative small-animal PET data with recovery coefficients: a phantom and rat study.
Aide N, Louis MH, Dutoit S, Labiche A, Lemoisson E, Briand M, Nataf V, Poulain L, Gauduchon P, Talbot JN, Montravers F.

Nucl Med Commun. 2007 Oct;28(10):813-22.

2007

Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS.

Neuro Oncol. 2007 Oct;9(4):412-23.

2007

A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment.
Le Moguen K, Lincet H, Marcelo P, Lemoisson E, Heutte N, Duval M, Poulain L, Vinh J, Gauduchon P, Baudin B.
Proteomics. 2007 Nov;7(22):4090-101.

2007

Cell surface overexpression of alphavbeta5 integrin impedes alphavbeta3-mediated migration of the human ovarian adenocarcinoma cell line IGROV1.
Maubant S, Leroy-Dudal J, Carreiras F, Deslandes E, Duigou F, Staedel C, Gauduchon P.

Cell Biol Int. 2007 Feb;31(2):109-18.

2007

Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression.
Villedieu M, Briand M, Duval M, Héron JF, Gauduchon P, Poulain L.

Gynecol Oncol. 2007 May;105(2):373-84.

2007

Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L.

Gynecol Oncol. 2007 Apr;105(1):31-44.

2006

Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
Le Moguen K, Lincet H, Deslandes E, Hubert-Roux M, Lange C, Poulain L, Gauduchon P, Baudin B.

Proteomics. 2006 Oct;6(19):5183-92.

2006

Intraperitoneal linear polyethylenimine (L-PEI)-mediated gene delivery to ovarian carcinoma nodes in mice.
Louis MH, Dutoit S, Denoux Y, Erbacher P, Deslandes E, Behr JP, Gauduchon P, Poulain L.

Cancer Gene Ther. 2006 Apr;13(4):367-74.

2006

Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment.
Villedieu M, Deslandes E, Duval M, Héron JF, Gauduchon P, Poulain L.

Gynecol Oncol. 2006 Jun;101(3):507-19.

2006

Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro.
Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, Schwartz L, Icard P.

Anticancer Res. 2006 Sep-oct;26(5A):3561-6.

2005

Control of low-resolution scanning of ovarian tumor stromal compartment.
Elie N, Labiche A, Michels JJ, Herlin P.

Image Analysis and stereology, 2005, 24, 85-93

2005

Optimal resolution for automatic quantification of blood vessels on digitized images of the whole cancer section.
Françoise R, Michels JJ, Plancoulaine B, Herlin P.

Image Anal Stereol 2005;24:59-67

2005

Adhesion of human ovarian adenocarcinoma IGROV1 cells to endothelial cells is partly mediated by the alphav integrins-vitronectin adhesive system and induces an alteration of endothelial integrity.
Leroy-Dudal J, Heyman J L, Gauduchon P, Carreiras F.

Cell Biol Int. 2005 Jun;29(6):482-8.

2005

Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alpha-v integrins and participation of MMP2.
Leroy-Dudal J, Demeilliers C, Gallet O, Dutoit S, Agniel R, Gauduchon P, Carreiras F.

Int J Cancer. 2005 Apr 20;114(4):531-43.

2005

Expression of alpha-V associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinium-based regimens.
Maubant S, Cruet-Hennequart S, Dutoit S, Denoux Y, Crouet H, Henry-Amar M, Gauduchon P.

J Mol Histol. 2005 Feb;36(1-2):119-29.

2004

Flow cytometry in primary breast carcinomas. prognostic impact of s-phase according to different analyses patterns.
Michels JJ, Marnay J, Plancoulaine B, Chasle J.

Cytometry. 2004 May;59B(1):32-9

2004

The cyclin-dependent kinase inhibitor p21cip1/waf1 enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells.
Ziller C, Lincet H, Muller CD, Staedel C, Behr JP, Poulain L.

Cancer Letters, 2004 Aug, 212 : 43-52

2003

Alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells.
Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C, Dedhar S.

Oncogene 2003: 1688-702.

2003

A simple way of quantifying immunostained cell nuclei on the whole histologic section.
Elie N, Plancoulaine B, Signolle JP, Herlin P.

Cytometry, Volume 56A, Issue 1, 37-45, 2003.

2003

An original approach for quantification of blood vessels on the whole tumour section.
Tran TKN, Elie N, Plancoulaine B, Herlin P, Coster M.

Anal Cell Pathol. 2003;25(2):63-75.